Trial | NCT00597051  Report issue

Title

Study of 3 Doses of ARD-0403 in Testosterone Deficient Men
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Multi-Centre Study of the Pharmacokinetics and Tolerability of 3 Different Doses of ARD-0403 in Testosterone Deficient Men

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    42
The purpose of this study is to determine which dose, if any, results in testosterone levels within the normal range for men.
Study Started
Oct 31
2005
Primary Completion
Feb 28
2006
Study Completion
Feb 28
2006
Last Update
Jan 17
2008
Estimate

Drug ARD-0403

Criteria 

Inclusion Criteria:

Testosterone deficiency
Normal BMI

Exclusion Criteria:

Previous treatment with testosterone replacement therapy within 4 weeks
Moderate-severe benign prostatic hypertrophy, or prostatic cancer
Haematocrit >50%
No Results Posted